• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

复发性套细胞淋巴瘤表现为四肢软组织肿瘤:迈阿密大学的经验和文献复习。

Relapsed mantle cell lymphoma manifesting with soft tissue tumors of the extremities: University of Miami experience and review of the literature.

机构信息

Department of Internal Medicine, Johns Hopkins Hospital, Baltimore, MD, USA.

Division of Hematology, Department of Medicine, University of Miami and Sylvester Comprehensive Cancer Center, 1475 NW 12th Ave (D8-4), Miami, FL, 33136, USA.

出版信息

Ann Hematol. 2024 Nov;103(11):4581-4588. doi: 10.1007/s00277-024-05997-1. Epub 2024 Sep 17.

DOI:10.1007/s00277-024-05997-1
PMID:39287654
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11534829/
Abstract

Mantle cell lymphoma (MCL) is frequently diagnosed at advanced stages and is characterized by multiple extranodal sites of disease, most notably the bone marrow, peripheral blood, and gastrointestinal tract. Historically the prognosis of mantle cell lymphoma has been poor with median survival of four to five years. With new treatment regimens, however, patients have been able to achieve prolonged remissions and require special attention while being evaluated for relapse. This report describes four patients treated for stage IV mantle cell lymphoma at the University of Miami who developed soft tissue relapse presenting as non-tender large masses of the extremities, including one patient who presented without associated nodal involvement. Average time to soft tissue relapse was 99 months (range: 28-240) following initial diagnosis. Providers who care for patients with mantle cell lymphoma should be aware of soft tissue lesions as a presentation of mantle cell lymphoma that merits evaluation for disease relapse.

摘要

套细胞淋巴瘤(MCL)常被诊断为晚期,其特征是存在多个结外疾病部位,最常见的是骨髓、外周血和胃肠道。从历史上看,套细胞淋巴瘤的预后一直很差,中位生存期为四到五年。然而,随着新的治疗方案的出现,患者已经能够实现长期缓解,并且在评估复发时需要特别注意。本报告描述了在迈阿密大学接受治疗的四例 IV 期套细胞淋巴瘤患者,这些患者出现了软组织复发,表现为四肢无痛性巨大肿块,其中一例患者无相关淋巴结受累。首次诊断后,软组织复发的平均时间为 99 个月(范围:28-240)。治疗套细胞淋巴瘤的医生应该意识到软组织病变是套细胞淋巴瘤的一种表现,需要评估疾病是否复发。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84a6/11534829/5002e4e8c5bc/277_2024_5997_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84a6/11534829/d7eb398618f6/277_2024_5997_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84a6/11534829/5002e4e8c5bc/277_2024_5997_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84a6/11534829/d7eb398618f6/277_2024_5997_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84a6/11534829/5002e4e8c5bc/277_2024_5997_Fig2_HTML.jpg

相似文献

1
Relapsed mantle cell lymphoma manifesting with soft tissue tumors of the extremities: University of Miami experience and review of the literature.复发性套细胞淋巴瘤表现为四肢软组织肿瘤:迈阿密大学的经验和文献复习。
Ann Hematol. 2024 Nov;103(11):4581-4588. doi: 10.1007/s00277-024-05997-1. Epub 2024 Sep 17.
2
From the archives of MD Anderson Cancer Center: Untreated leukemic non-nodal mantle cell lymphoma with relapse as pleomorphic variant mantle cell lymphoma 21 years later.来自MD安德森癌症中心档案:未经治疗的白血病性非结外型套细胞淋巴瘤,21年后复发为多形性变异型套细胞淋巴瘤
Ann Diagn Pathol. 2021 Feb;50:151649. doi: 10.1016/j.anndiagpath.2020.151649. Epub 2020 Oct 24.
3
Mantle cell lymphoma in the ocular adnexal region.眼附属器区域的套细胞淋巴瘤。
Ophthalmology. 2005 Jan;112(1):114-9. doi: 10.1016/j.ophtha.2004.07.025.
4
Giant mantle cell lymphoma in the soft tissue of the leg: rare presentation.腿部软组织巨大套细胞淋巴瘤:罕见表现。
Tumori. 2021 Dec;107(6):NP49-NP53. doi: 10.1177/03008916211001925. Epub 2021 Mar 22.
5
Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents.精准医学时代的套细胞淋巴瘤——诊断、生物标志物与治疗药物
Oncotarget. 2016 Jul 26;7(30):48692-48731. doi: 10.18632/oncotarget.8961.
6
Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.吉西他滨、异环磷酰胺、奥沙利铂和利妥昔单抗(R-GIFOX),一种用于复发难治性侵袭性非霍奇金淋巴瘤的新型有效减瘤/动员挽救方案:一项试点研究的结果
Ann Oncol. 2006 May;17 Suppl 4:iv18-24. doi: 10.1093/annonc/mdj994.
7
Emerging therapy for the treatment of mantle cell lymphoma.新兴疗法治疗套细胞淋巴瘤。
J Natl Compr Canc Netw. 2014 Sep;12(9):1311-8; quiz 1318. doi: 10.6004/jnccn.2014.0126.
8
Clinicopathological Features of Ocular Adnexal Mantle-Cell Lymphoma in an International Multicenter Cohort.眼附属器黏膜相关边缘区 B 细胞淋巴瘤的临床病理特征:一项国际多中心队列研究
JAMA Ophthalmol. 2017 Dec 1;135(12):1367-1374. doi: 10.1001/jamaophthalmol.2017.4810.
9
Radiation therapy is an effective modality in the treatment of mantle cell lymphoma, even in heavily pretreated patients.放射治疗是治疗套细胞淋巴瘤的一种有效方式,即使是在经过大量前期治疗的患者中也是如此。
Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):474-9. doi: 10.1016/j.clml.2014.07.003. Epub 2014 Jul 15.
10
Mantle cell lymphoma: state of the art.套细胞淋巴瘤:最新进展
Clin Adv Hematol Oncol. 2015 Jan;13(1):44-55.

本文引用的文献

1
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.伊布替尼联合免疫化疗联合或不联合自体造血干细胞移植与免疫化疗和自体造血干细胞移植治疗未经治疗的套细胞淋巴瘤患者(TRIANGLE):欧洲套细胞淋巴瘤网络的一项三臂、随机、开放标签、III 期优效性试验。
Lancet. 2024 May 25;403(10441):2293-2306. doi: 10.1016/S0140-6736(24)00184-3. Epub 2024 May 2.
2
Skin Involvement by Hematological Neoplasms with Blastic Morphology: Lymphoblastic Lymphoma, Blastoid Variant of Mantle Cell Lymphoma and Differential Diagnoses.具有母细胞形态的血液系统肿瘤累及皮肤:淋巴母细胞淋巴瘤、套细胞淋巴瘤母细胞样变异型及鉴别诊断
Cancers (Basel). 2023 Aug 2;15(15):3928. doi: 10.3390/cancers15153928.
3
Primary Soft-Tissue Lymphomas: MRI Features Help Discriminate From Other Soft-Tissue Tumors.原发性软组织淋巴瘤:MRI特征有助于与其他软组织肿瘤相鉴别。
Acad Radiol. 2023 Feb;30(2):285-299. doi: 10.1016/j.acra.2022.08.009. Epub 2022 Sep 7.
4
Mantle-Cell Lymphoma.套细胞淋巴瘤
N Engl J Med. 2022 Jun 30;386(26):2495-2506. doi: 10.1056/NEJMra2202672.
5
Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma.评估套细胞淋巴瘤的真实世界治疗模式和结局。
Blood Adv. 2022 Jul 26;6(14):4122-4131. doi: 10.1182/bloodadvances.2022007247.
6
New Directions for Mantle Cell Lymphoma in 2022.2022 年套细胞淋巴瘤的新方向。
Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-15. doi: 10.1200/EDBK_349509.
7
Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.2022 年的套细胞淋巴瘤——分子发病机制、风险分层、临床方法以及现有和新型治疗的全面更新。
Am J Hematol. 2022 May;97(5):638-656. doi: 10.1002/ajh.26523.
8
Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes.套细胞淋巴瘤的一线免疫化疗进展及其对生存结局的影响。
Blood Adv. 2022 Feb 22;6(4):1350-1360. doi: 10.1182/bloodadvances.2021005715.
9
Giant mantle cell lymphoma in the soft tissue of the leg: rare presentation.腿部软组织巨大套细胞淋巴瘤:罕见表现。
Tumori. 2021 Dec;107(6):NP49-NP53. doi: 10.1177/03008916211001925. Epub 2021 Mar 22.
10
R-MACLO-IVAM regimen followed by maintenance therapy induces durable remissions in untreated mantle cell lymphoma - Long term follow up results.R-MACLO-IVAM 方案联合维持治疗可诱导未经治疗的套细胞淋巴瘤获得持久缓解 - 长期随访结果。
Am J Hematol. 2021 Jun 1;96(6):680-689. doi: 10.1002/ajh.26163. Epub 2021 Apr 7.